These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15848570)

  • 1. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
    Tan J; Yang S; Wu W
    Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids.
    Turconi A; Rilo LR; Goldberg J; de Boccardo G; Garsd A; Otero A
    Transplant Proc; 2005 Mar; 37(2):672-4. PubMed ID: 15848497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab (Simulect) in acute tubular necrosis high-risk kidney transplantation.
    Rivera CF; Hernández AA; Verdejo PV; García JO; Rego SC; Cañedo FV
    Transplant Proc; 2005 Nov; 37(9):3733-5. PubMed ID: 16386521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
    Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
    Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
    Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
    Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
    Balbontin F; Kiberd B; Fraser A; Kiberd M; Lawen J
    Clin Transplant; 2005 Apr; 19(2):225-9. PubMed ID: 15740559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function.
    Fernandez Rivera C; Alonso Hernandez A; Villaverde Verdejo P; Oliver García J; Valdés Cañedo F
    Transplant Proc; 2005 Apr; 37(3):1435-7. PubMed ID: 15866629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD; Rajagopalan PR; Hall M
    Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulect induction facilitates Neoral-based steroid-free immunosuppression in primary kidney transplant recipients.
    Kung SC; Parikh M; Fyfe B; Xiao SG; Sierka D; Heifets M; Moritz M; Anil Kumar MS
    Transplant Proc; 2004 Mar; 36(2 Suppl):475S-477S. PubMed ID: 15041391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG; Davies EA; Mourad G; Oppenheimer F; Molina MG; Rostaing L; Wilkinson AH; Mulloy LL; Bourbigot BJ; Prestele H; Korn A; Girault D;
    Transplantation; 2003 Jan; 75(1):37-43. PubMed ID: 12544868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D; Kotnik V; Kandus A
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of simulect can reduce the incidence of acute rejection and demonstrates with superior 3-year patient and graft survival rates in renal transplantation.
    Chu SH; Chiang YJ; Huang CC; Lee PH; Hu RH; Lai MK; Chueh SC; Tsai MK
    Transplant Proc; 2004 Sep; 36(7):2108-9. PubMed ID: 15518763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.